依达拉奉右莰醇联合丁苯酞治疗急性 脑梗死临床疗效及相关机制研究

Study on the Clinical Efficacy and Related Mechanisms of the Edaravone Dexborneol Combine with Butylphthalide in the Treatment of Acute Cerebral Infarction

摘要:

〔摘 要〕 目的：探讨依达拉奉右莰醇与丁苯酞联合治疗对急性脑梗死（ACI）患者神经生长因子、血液流变学的影响。 方法：按照随机数字表法将 2021 年 2 月至 2023 年 6 月邵武市立医院收治的 84 例 ACI 患者分为观察组和对照组，分别为 42 例。对照组采用丁苯酞治疗，观察组在对照组基础上加用依达拉奉右莰醇治疗。比较两组患者临床疗效、不良反应发生 情况以及治疗前后神经生长因子水平、血液流变学指标、生活质量。 结果：两组比较，观察组患者临床总有效率较高，差 异具有统计学意义（P ＜ 0.05）。两组患者不良反应发生率比较，差异无统计学意义（P ＞ 0.05）。治疗 14 d 后，两组比较， 观察组患者内皮素 –1 水平、血液流变学指标均较低，血管内皮生长因子、一氧化氮水平、各项健康调查量表（SF–36）评 分均较高，差异具有统计学意义（P ＜ 0.05）。 结论：应用丁苯酞联合依达拉奉右莰醇治疗，可促进 ACI 患者神经生长因 子水平改善，调节血液流变学，提升神经功能，且安全可靠。

Abstract:

〔Abstract〕 Objective To investigate the effects of edaravone dexborneol combined with butylphthalide on nerve growth factor and hemorheology in patients with acute cerebral infarction (ACI). Methods According to random number table method, 84 patients with ACI admitted to Shaowu Municipal Hospital from February 2021 to June 2023 were divided into a control group and an observation group, with 42 cases in each group. The control group was treated with butylphthalide, and the observation group was treated with edaravone dexborneol. The clinical efficacy, occurrence of adverse reactions, nerve growth factor level, hemorheology index and quality of life before and after treatment were compared between the two groups. Results Compared with the control group, the total clinical effective rate of the observation group was higher, and the difference was statistically significant (P < 0.05). There was no significant difference in the incidence of adverse reactions between the two groups (P > 0.05). After 14 days of treatment, compared with the control group, the levels of endothelin-1 and hemorheology indexes in the observation group were lower, and the level of vascular endothelial growth factor, nitric oxide and scores of 36-item short form health survey (SF-36) were higher in the observation group, with statistical significance (P < 0.05). Conclusion Treatment with butylphthalide combined with edaravone dexborneol can improve the levels of nerve growth factor, regulate hemorheology, and enhance nerve function in ACI patients, and is safe and reliable.